Patents by Inventor Jason Edward BRITTAIN
Jason Edward BRITTAIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200237726Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.Type: ApplicationFiled: November 26, 2019Publication date: July 30, 2020Inventors: Jason Edward Brittain, Joe Craig Franklin
-
Publication number: 20180296534Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.Type: ApplicationFiled: June 19, 2018Publication date: October 18, 2018Inventors: Jason Edward Brittain, Joe Craig Franklin
-
Patent number: 9688624Abstract: Described herein is the DP2 antagonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.Type: GrantFiled: January 5, 2011Date of Patent: June 27, 2017Assignee: Brickell Biotech, Inc.Inventors: Jason Edward Brittain, Christopher David King, Brian Andrew Stearns
-
Publication number: 20170121295Abstract: Described herein is the LPA1 antagonist 1-{4?-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.Type: ApplicationFiled: December 16, 2016Publication date: May 4, 2017Applicants: AMIRA PHARMACEUTICALS, INC., BRISTOL-MYERS SQUIBB COMPANYInventors: Jason Edward BRITTAIN, Thomas Jon SEIDERS, Christopher David KING, Victor W. ROSSO
-
Patent number: 9572785Abstract: Described herein is the DP2 antagonist [2?-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4?-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.Type: GrantFiled: August 25, 2014Date of Patent: February 21, 2017Assignee: Brickell Biotech, Inc.Inventors: Jason Edward Brittain, Brian Andrew Stearns, Christopher David King, Kevin Ross Holme
-
Patent number: 9556133Abstract: Described herein is the LPA1 antagonist 1-{4?-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.Type: GrantFiled: December 7, 2011Date of Patent: January 31, 2017Assignees: BRISTOL-MYERS SQUIBB COMPANY, AMIRA PHARMACEUTICALS, INC.Inventors: Jason Edward Brittain, Thomas Jon Seiders, Christopher David King, Victor W. Rosso
-
Publication number: 20160136119Abstract: Described herein is the DP2 antagonist [2?-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4?-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.Type: ApplicationFiled: August 25, 2014Publication date: May 19, 2016Inventors: Jason Edward Brittain, Brian Andrew Stearns, Christopher David King, Kevin Ross Holme
-
Publication number: 20150374671Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.Type: ApplicationFiled: September 4, 2015Publication date: December 31, 2015Inventors: Jason Edward Brittain, Joe Craig Franklin
-
Patent number: 8895756Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.Type: GrantFiled: December 19, 2012Date of Patent: November 25, 2014Assignee: Cephalon, Inc.Inventors: Jason Edward Brittain, Joe Craig Franklin
-
Patent number: 8815917Abstract: Described herein is the DP2 antagonist [2?-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4?-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.Type: GrantFiled: July 29, 2010Date of Patent: August 26, 2014Assignee: Panmira Pharmaceuticals, LLCInventors: Jason Edward Brittain, Brian Andrew Stearns, Christopher David King, Kevin Ross Holme
-
Patent number: 8791270Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.Type: GrantFiled: August 19, 2013Date of Patent: July 29, 2014Assignee: Cephalon, Inc.Inventors: Jason Edward Brittain, Joe Craig Franklin
-
Publication number: 20140148490Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.Type: ApplicationFiled: January 31, 2014Publication date: May 29, 2014Applicant: Cephalon, Inc.Inventors: Jason Edward Brittain, Joe Craig Franklin
-
Publication number: 20130338205Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.Type: ApplicationFiled: August 19, 2013Publication date: December 19, 2013Applicant: Cephalon, Inc.Inventors: Jason Edward Brittain, Joe Craig Franklin
-
Patent number: 8609863Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.Type: GrantFiled: December 19, 2012Date of Patent: December 17, 2013Assignee: Cephalon, Inc.Inventors: Jason Edward Brittain, Joe Craig Franklin
-
Publication number: 20130253023Abstract: Described herein is the LPA1 antagonist 1-{4?-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-bi-phenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.Type: ApplicationFiled: December 7, 2011Publication date: September 26, 2013Inventors: Jason Edward Brittain, Thomas Jon Seiders, Christopher David King, Victor W. Rosso
-
Patent number: 8461350Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.Type: GrantFiled: October 18, 2012Date of Patent: June 11, 2013Assignee: Cephalon, Inc.Inventors: Jason Edward Brittain, Joe Craig Franklin
-
Publication number: 20130131131Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.Type: ApplicationFiled: December 19, 2012Publication date: May 23, 2013Inventors: Jason Edward Brittain, Joe Craig Franklin
-
Publication number: 20130123316Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.Type: ApplicationFiled: December 19, 2012Publication date: May 16, 2013Inventors: Jason Edward Brittain, Joe Craig Franklin
-
Patent number: 8436190Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.Type: GrantFiled: January 12, 2006Date of Patent: May 7, 2013Assignee: Cephalon, Inc.Inventors: Jason Edward Brittain, Joe Craig Franklin
-
Publication number: 20130053444Abstract: Described herein is the DP2 anatgonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 anatgonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 anatgonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.Type: ApplicationFiled: January 5, 2011Publication date: February 28, 2013Applicant: PANMIRA PHARMACEUTICALS, LLCInventors: Jason Edward Brittain, Christopher David King, Brian Andrew Stearns